^
Association details:
| Biomarker: | MSLN overexpression + PD-L1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ATA3271 (Mesothelin-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
Published date:
11/12/2020
Excerpt:
In vivo, ATA3271 exhibited potent antitumor activity and significant survival benefit in mice implanted with MGM-PDL1 cells that highly express both mesothelin as well as PD-L1.
